Separately, NICE in their guidance (April 2019) had also recommended daratumumab plus bortezomib plus dexamethasone for use within the Cancer Drugs Fund as an option for treating relapsed multiple myeloma in people who have had 1 previous treatment. It is recommended only if the conditions in the managed access agreement for daratumumab plus bortezomib plus dexamethasone are followed.